Medicare AdvantageDocumentationMedium impact
Implantable and External Infusion Pumps for Pain or Spasticity - Medicare Advantage (Revised)
Humana·Pain Management, Neurology, Neurosurgery +2 more·Pharmacy
Effective date
Jul 1, 2026
We identified it
Jun 30, 2026
Summary
This revised Medicare Advantage policy (effective 07/01/2026) establishes specific clinical criteria for implantable and external infusion pumps for pain and spasticity management. Key changes include: requiring a baseline Modified Ashworth Scale score of ≥3 for baclofen trials, mandating a 2-point MAS reduction for permanent implantation, and defining 'failure of conservative therapy' requirements with a 50% pain reduction threshold for opioid/non-opioid trials. The policy also clarifies replacement/revision criteria and addresses postoperative external pumps.
Action Required
By 06/01/2026: Billing and clinical teams must update prior authorization protocols and medical necessity documentation requirements. (1) Modify PA templates to require: baseline MAS score ≥3 for intrathecal baclofen trials (CPT 62322-62327, C2626); documented failure of conservative therapy for pain management trials; and 50% pain reduction confirmation for permanent pain pump implantations. (2) Update provider encounter forms and clinical notes to capture Modified Ashworth Scale scores pre- and post-trial. (3) Train coding staff on geographic MAC jurisdictions (DME MACs A-D and Part A/B MACs JE, JF, JJ, JM) and ensure correct LCD application per state. (4) Review existing pending claims for spasticity/pain pump procedures and re-submit with updated MAS documentation if previously lacking. (5) Coordinate with providers to ensure trial data collection and documentation of clinical outcomes before requesting permanent implant authorization. Non-compliance will result in claim denials for insufficient documentation of severity metrics and trial success thresholds.